Advanced Prostate Cancer
ASCO GU 2019
ASCO GU 2019: Outcome of Men with Relapses after Adjuvant BEP for Clinical Stage I Nonseminoma
ASCO GU 2019: A Phase II, Open-label, Multi-arm Study of TAS-115 for Castration-resistant Prostate Cancer Patients with Bone Metastases
ASCO GU 2019: Long-term Outcomes of Hypoxia Modification in Bladder Preservation: Update from BCON Trial
ASCO GU 2019: A Randomized Trial Comparing Fluorocholine-PET/CT with Conventional Imaging in Prostate Cancer
ASCO GU 2019: Discussion on: The ARAMIS Trial, the Final Analysis of LATITUDE Study, and the ARCHES Trial
ASCO GU 2019: Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-Resistant Prostate Cancer
ASCO GU 2019: ARCHES Trial-Phase 3 Study of ADT with Enzalutamide in mHSPC
ASCO GU 2019: Keynote-365: Pembrolizumab Plus Olaparib in Docetaxel Pretreated Patients with Metastatic Castrate-resistant Prostate Cancer
ASCO GU 2019: Final Analysis of LATITUDE, A Phase III in Patients with Newly Diagnosed High-risk Metastatic Castration-naïve Prostate Cancer
ASCO GU 2019: Skeletal Related Events in CTRIAL-IE 13-21: Radium-223 in Combination with Enzalutamide for Patients with mCRPC
ASCO GU 2019: Phase II Study of Niraparib in Patients with Metastatic Castration-Resistant Prostate Cancer and Biallelic DNA-Repair Gene Defects : Preliminary Results of GALAHAD
ASCO GU 2019: Updated Analysis of Progression-Free Survival with First Subsequent Therapy and Safety in the SPARTAN Study of Apalutamide in Patients with High-Risk Nonmetastatic Castration-Resistant Prostate Cancer
ASCO GU 2019: A Multicentric Phase II Randomized Trial of Docetaxel plus Enzalutamide versus Docetaxel as First Line Chemotherapy for Patients with Metastatic Castration-Resistant Prostate Cancer: CHEIRON Study
ASCO GU 2019: Intensification Versus Deintensification in High-Risk Prostate Cancer
ASCO GU 2019: A Phase III Trial of Docetaxel versus Docetaxel and Radium-223 in Patients with Metastatic Castration-Resistant Prostate Cancer: DORA
ASCO GU 2019: Cost-Effectiveness of Metastasis-Directed Therapy in the Setting of Oligometastatic Hormone-Sensitive Prostate Cancer
ASCO GU 2019: Quality of Life-Focused Decision-Making for Castrate-Sensitive Prostate Cancer
ARAMIS: Efficacy and Safety of Darolutamide in nmCRPC | ASCO GU 2019
Breaking News: Darolutamide Receives FDA Approval for the Treatment of Non-metastatic Castration-resistant Prostate Cancer
San Francisco, CA (UroToday.com) The use of androgen-axis targeted agents, specifically enzalutamide and abiraterone, have drastically changed the landscape of advanced prostate cancer management. Just last year, at GU ASCO 2018, two landmark trials were presented – SPARTAN and PROSPER - which were conducted in nonmetastatic CRPC (nmCRPC) patients.1,2 PROSPER specifically assesses enzalutamide in the M0 CRPC setting, while SPARTAN focused on apalutamide-ARN-509 (APA). Apalutamide is a next-generation competitive inhibitor of the androgen receptor under development for the treatment of patients with prostate cancer but perhaps with greater potency and reduced CNS effects. Both demonstrated ~2 year metastases-free survival benefit compared to ADT alone and there was early evidence of OS benefit.
ASCO GU 2019: Discussion on: Results of Checkmate 650 and Circulating Tumor Cell Number as a Transitional Surrogate Endpoint for Survival in mCRPC Trials
Sipulecel-T is the only immunotherapy currently approved in patients with mCRPC. Previous trials have shown no improvement in outcomes for PROSTVAC and GVAX. Ipilimumab also did not demonstrate survival benefits in patients who were chemotherapy naïve asymptomatic or minimally symptomatic or post-docetaxel and bone-directed radiotherapy.